Data and Code for: Effective Health Aid: Evidence from Gavi’s Vaccine Program

Principal Investigator(s): View help for Principal Investigator(s) Gauri Kartini Shastry, Wellesley College; Daniel Tortorice, College of the Holy Cross

Version: View help for Version V1

Name	File Type	Size	Last Modified
GBD			09/20/2023 08:12:AM
WB_countries_Admin0_10m			09/20/2023 08:29:AM
coverage-estimates-series			09/20/2023 08:28:AM
All-Countries-Commitments-and-Disbursements Approvals.csv	text/csv	120 KB	01/23/2020 10:50:AM
Coverage_survey_data.csv	text/csv	4.7 MB	02/17/2022 07:24:AM
Gavi Vaccine Introduction Dates Database.csv	text/csv	29.4 KB	07/15/2024 09:42:AM
WDIEXCEL.csv	text/csv	118 MB	09/20/2023 04:10:AM
child_cod_2000-2019.dta	application/x-stata-dta	1.9 MB	09/20/2023 04:08:AM
isocodes.csv	text/csv	8.2 KB	10/31/2019 07:29:AM

Project Description

Summary: Gavi, the Vaccine Alliance has provided over US$16 billion in funding for vaccination expansion in low- and middle-income countries since its founding in 1999. We exploit differential timing in Gavi support across countries and vaccines to estimate the effects of this large-scale public health initiative. We find that Gavi’s support for a vaccine increased coverage rates by 2 – 5 percentage points across all vaccines, on average, and by 10 – 20 percentage points for newer vaccines. We also find that Gavi’s support for a vaccine reduced child mortality from related causes by 1 child per 1,000 live births. We estimate these improvements saved around 1.6 million lives at a notably low cost of US$8,750 per life saved.

Scope of Project

Subject Terms: child health; development; vaccination; foreign aid

JEL Classification:
      F35 Foreign Aid
      I15 Health and Economic Development
      O10 Economic Development: General

Related Publications

Download this project

Published Versions

V1 [2025-04-04]

Export Metadata

Dublin Core

DDI 2.5

Report a Problem

Found a serious problem with the data, such as disclosure risk or copyrighted content? Let us know.

This material is distributed exactly as received from the data depositor. As of April 2026, depositors are required to submit study materials in accessible formats. ICPSR has not reviewed, checked, or processed this material. For additional information about the study, please contact the investigator(s) directly. If you have questions about the accessibility of materials distributed by ICPSR or require further assistance, please visit ICPSR's Accessibility Center.